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Abstract. The characteristics of terbium-161 diethylene 
triamine penta-acetic acid (DTPA) labelled octreotide 
with respect to specific binding to somatostatin (octreo- 
tide) receptors on rat brain cortex membranes, biological 
activity, uptake and excretion by isolated perfused rat 
livers and metabolism in vivo in normal and tumour- 
bearing rats were determined and compared to those of 
indium-111 DTPA-octreotide. The results of the binding 
studies demonstrate that 16~Tb-DTPA-octreotide is a 
high-affinity radioligand for somatostatin receptors, with 
an affinity comparable to that of ~HIn-DTPA-octreotide. 
Rat growth hormone secretion inhibition experiments 
showed that 16~Tb-DTPA-octreotide has a similar poten- 
cy to U lIn-DTPA-octreotide. ~61Tb-DTPA-octreotide ap-
peared to be taken up even less by the isolated perfused 
rat liver than 11 qn-DTPA-octreotide, asalmost no tracer 
disappeared from the perfusion medium. Furthermore, 
hardly any radioactivity was found in the liver, and ex- 
cretion into the bile was negligible. The biodistribution 
studies showed that for octreotide receptor-positive or-
gans, such as pancreas and adrenals, uptake of 161Tb- 
DTPA-octreotide is lower then that of 111In-DTPA-oct- 
reotide. However, as the clearance from the blood of the 
former compound is faster than that of the latter, the tis- 
sue/blood ratio is higher in the case of 16~Tb-DTPA-oc- 
treotide than with ~HIn-DTPA-octreotide. Furthermore, 
these studies demonstrated that the uptake of ~61Tb- 
DTPA-octreotide by the renal tubular cells after glomer- 
ular filtration can be reduced by administration f lysine 
or sodium maleate. Increase in urine production before 
and during the experiment had no effect on the kidney 
uptake of t61Tb-DTPA-octreotide. Finally, it appeared 
that a maximal abelling efficiency of 161Tb-DTPA-oc- 
treotide is essential, as with decreasing efficiency the up- 
take in the octreotide receptor-positive organs decreased, 
whereas non-specific uptake in the other organs was in- 
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creased. It is concluded that, on the basis of the favour- 
able physical characteristics of 16~Tb combined with the 
in vitro and in vivo studies performed with 161Tb-DTPA- 
octreotide, the latter is a promising radiopharmaceutical 
for both intraoperative scanning and radiotherapy. Stud- 
ies in patients need to be performed now to see whether 
16~Tb-DTPA-octreotide can indeed open new therapeutic 
applications for patients bearing octreotide receptor-pos- 
itive tumours. 
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Introduction 
Indium-Ill diethylene triamine penta-acetic acid la- 
belled octreotide (OcreoScan) is a radiopharamaceutical 
that binds to the somatostatin receptor present in certain 
tissues. It is being used for scintigraphic maging of so- 
matostatin receptor-positive lesions, such as gastro-intes- 
tinal pancreatic tumours, neuroblastoma, phaeochromo- 
cytoma, breast cancer, Hodgkin's lymphoma nd small 
cell lung cancer [1]. 
Since the availability of this and other radiolabelled 
somatostatin a alogues for in vivo imaging, the range of 
diagnostic applications under study is rapidly increased. 
One example is the intraoperative scanning using gam- 
ma rays emitting radiolabelled somatostatin analogues. 
This technique is used to guide surgery with respect o 
the localisation of small somatostatin receptor-positive 
tumours using a small hand-held probe [2, 3]. Another 
field of application that is under examination is the po- 
tential use of radiolabelled peptide for radiotherapy. 
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However, for these two purposes, 111in will not be the 
radionuclide of first choice. While its characteristics are 
favourable for scintigraphy (gamma rays of 174 and 247 
keV), they are not optimal for intraoperative scanning 
because of the high background radiation due to the rela- 
tively hard gamma rays emitted by thin. Furthermore, 
for radiotherapy a beta particle-emitting radionuclide is 
more suitable. 
We have now investigated whether DTPA-octreotide 
labelled with terbium-161 is suitable for the above-men- 
tioned applications. The characteristics of 161Tb are quite 
ideal for intraoperative scanning: low-energy gamma 
rays (with peaks of 46-48 and 74 keV) and a half-life of 
6.91 days. As for the potential use for radiotherapy, 
161Tb emits beta rays of 135, 154 and 180 keV. There- 
fore, the characteristics of 161Tb-DTPA-octreotide with 
respect o specific binding to somatostatin (octreotide) 
receptors on rat brain cortex membranes, biological ac- 
tivity, handling in isolated perfused rat livers and metab- 
olism in vivo and normal and tumour-bearing rats were 
determined and compared to those of ~HIn-DTPA-oc- 
treotide [4-6]. 
It appeared from our experiments that, like ~11In- 
DTPA-octreotide, 16tTb-DTPA-octreotide was mostly 
cleared from the body via the kidneys. In previous tud- 
ies, we found that in humans a significant amount of 
~HIn-DTPA-octreotide accumulates in the renal paren- 
chyma (about 7% of the injected dose, 4 h after injec- 
tions) because of re-uptake by the tubular cells after 
glomerular filtration [7]. This renal retention reduces 
both the scintigraphic sensitivity for detection of small 
turnouts in the abdomen and the potential use of the ra- 
diolabelled peptide for radiotherapy [8]. Therefore, we 
recently performed studies to determine whether enal 
uptake of l i qn-DTPA-octreotide could be reduced by in- 
hibiting tubular re-uptake in vivo in the rat [6]. In the 
present study, we tested the effects of increased urinary 
flow and administration of lysine (400 mg/kg) or of so- 
dium maleate (400 mg/kg) on tubular reabsorption of 
161Tb-DTPA-octreotide in vivo in rats. 
We also investigated the influence of the labelling ef- 
ficiency of DTPA-octreotide with 161Tb as well as of rat 
body mass (age) on organ distribution in rats. 
Materials and methods 
Radiolabelling and quality control of the radiopharmaceutical. 
[DTPA-D-Phel]octreotide and 161TBC13 were obtained from Mall- 
inckrodt Medical B.V. (Petten, The Netherlands). The radiolabel- 
ling (with 4 MBq) of [DTPA-D-PheJ]octreotide was performed es- 
sentially as described for 111In-DTPA-octreotide [4], except hat 20 
gg DTPA-octreotide instead of 10 ug and acetate instead of citrate 
buffer were used. Only when labelling efficiency was >_95% was 
the radiolabelled product used for experiments, unless otherwise 
stated. The 161Tb was produced at the Free University of Brussels, 
Belgium, from gadolinium-160 that was irradiated with neutrons. 
The first product after this reaction, 161Gd, decays to ~61Tb (half- 
life 3.6 min). The latter is chemically separated from Gd. 
Highly purified and fatty acid-free bovine serum albumin 
(BSA; Boseral) was a product of Organon Teknika (Oss, The 
Netherlands). All other reagents were of the highest purity com- 
mercially available. 
In vitro receptor binding studies. Receptor binding assays were 
carried out using 161Tb-DTPA-octreotide as described previously 
for t~qn-DTPA-octreotide [4] using rat brain cortex membranes. 
Binding curves and ICs0 for displacement of 161Tb- DTPA-octreo- 
tide by unlabelled DTPA-octreotide or 159Tb- DTPA-octreotide 
were calculated using the computer fitting program of Graphpad 
(ISI software, Philadelphia, Pa., USA). 
Biological activity. The biological activity of stable 159Tb- DTPA- 
octreotide was assessed by measuring its potency to inhibit he se- 
cretion of rat growth hormone (rGH) from rat pituitary cells as de- 
scribed previously [4]. 
Isolated perfused rat liver studies. Livers of male Wistar rats 
(200-250 g) were isolated and perfused in a recirculating system 
at 37°C as described previously. [9]. The magnetically stirred 
perfusion medium used in all experiments was 150 ml Krebs- 
Ringer buffer (ll8mmol/1 NaC1, 5retool/1 KC1, 1.1 mmol/l 
MgSO 4, 2.5 mmol/1 CaC12, 1.2 mmol/1 KHzPO 4, and 25 mmol/1 
NaHCO3) supplemented with 10 mM glucose and 1% BSA. The 
pH of the medium was maintained at7.43 by gassing with carbo- 
gen (95% 02 and 5% CO2, 400 ml/min). The function of the liver 
was monitored by its outer appearance, measurement of hydrostat- 
ic pressure necessary to maintain a perfusion medium flow of 40 
ml/min, bile flow, and pH of the perfusion medium. Livers were 
preperfused for 30 rain. The experiment was started by addition of 
370 kBq of tracer to the stirred medium in the central reservoir. 
Subsequently, 0.5 ml medium samples were taken at l, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 and 60 min from a smaller 
medium reservoir, the height of which determines the hydrostatic 
pressure. Bile samples were collected at 10-min intervals. The 
samples were stored at -20 ° C until analysis. The chemical status 
of the radionuclide inmedium and bile samples was analysed as a 
function of time using instant hin-layer chromatography (ITLC- 
SG, Gelman Sciences, Ann Arbor, Mich., USA) in 1 M acetate 
buffer (pH 5) (not shown). 
Tissue distribution and specific binding of J61Tb- DTPA-octreotide 
in normal and tumour-bearing rats. Normal male Wistar or Lewis 
rats or tumour-bearing male Lewis rats (200-250 g, unless other- 
wise stated) were placed in metabolic ages 24 h prior to the ex- 
periment. Tumour-bearing rats carried the transplantable ratpan- 
creatic tumour CA20948, which has previously been shown to 
possess omatostatin receptors [10], in both upper hind legs. Me- 
tabolic cages were used to collect all (radioactive) urine produced 
during the experiment tofollow the urinary clearance of the radio- 
active compound. The rats were fed with normal rat chow (Hope 
Farms, Woerden, The Netherlands) or with 35 g/day of rat chow 
suspended in water (40-g pellets in 100 ml water). Drinking water 
was always available ad libitum. At t=0 h, rats were injected with 
0.2 MBq (0.5 ~tg) I6~Tb- DTPA-octreotide (radiochemical puri- 
ty>95%) into the dorsal vein of the penis (injected volume 200 gl) 
during ether anaesthesia. The radioactivity was measured in a 
dose calibrator (VDC-202, Veenstra, Jonre, The Netherlands). In 
order to determine non-specific binding of the radiopharmaceuti- 
cal, rats were injected subcutaneously with 0.5 mg octreotide 
(Sandoz, Basel, Switzerland) in 1 ml 0.05 M acetic acid in 154 
mmol/1 NaC1, 40 rain before injection of 16~Tb- DTPA-octreotide. 
European Journal of Nuclear Medicine Vol. 22, No. 7, July 1995 
610 
Twenty hours after injection of the radiolabelled product, rats 
were sacrificed (ether) and organs were isolated from the rats and 
subsequently analysed. The tissue distribution of the 16~Tb-la- 
belled somatostatin analogue was studied by measurement of ra- 
dioactivity in isolated organs as well as of blood samples, using a 
LKB- 1282-Compu-gammasystem. 
Possible renal re-uptake blockers tested. Lysine (400 mg/kg) and 
sodium maleate (400 mg/kg) were administered intravenously to 
the rats at physiological pH in volumes of 200 gl immediately be- 
fore 161Tb- DTPA-octreotide injection. 
Statistical analysis. Results are expressed as mean+SD of groups 
of at least three rats. Statistical evaluation was performed using 
one-way analysis of variance followed by comparison among 
class means and Student's t-test, corrected for multiple pairwise 
comparisons between means. 
Results 
In vitro receptor binding studies 
Rat brain cortex membranes were used to study the bind- 
ing of ~6~Tb-DTPA-octreotide to octreotide receptors in 
the presence of increasing amounts of t59Tb-DTPA-oc- 
treotide or unlabelled DTPA-octreotide (Fig. la). The 
binding of 161Tb-DTPA-octreotide creased in the pres- 
ence of increasing concentrations of both compounds, 
indicating that the binding process was saturable and 
specific. It is also shown that DTPA-octreotide competes 
somewhat better than 159Tb-DTPA-octreotide. The ICso 
values appeared to be in the nanomolar range, similar to 
that found for u tin_DTPA_octreotide [4]. 
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Fig. 1. a Binding of 16~Tb-DTPA-octreotide o rat brain cortex 
membranes in the presence of increasing concentrations ofDTPA- 
octreotide (A) or 159Tb-DTPA-octreotide (-k), expressed as the 
Biological activity 
Figure lb shows the effects of DTPA-octreotide and of 
159Tb-DTPA-octreotide on the secretion of rGH by cul- 
tured rat pituitary cells. The radiolabelled somatostatin 
analogue significantly inhibited rGH secretion in a dose- 
dependent manner, similar to lUIn-DTPA-octreotide [4]. 
Isolated perfused rat liver studies 
Table 1 shows that after 1 h perfusion of isolated rat liv- 
ers with lllIn-DTPA-octreotide, 2.3% of the dose was 
excreted in the bile, 1.7% was present in the liver, 
whereas 96% was still present in the perfusion medium. 
The data obtained with 16tTb-DTPA-octreotide show 
even less liver clearance: after 60 rain of perfusion, 
<0.1% of the dose was excreted in the bile, and 1.4% of 
the dose was present in the liver. 
Tissue distribution and specific binding of ~6~Tb-DTPA - 
octreotide in normal and tumour-bearing rats in vivo 
In Table 2 organ distribution of ~61Tb-DTPA-octreotide 
and llHn-DTPA-octreotide in normal rats is shown, ex- 
pressed as % of the injected dose (ID), 20 h after admin- 
istration. It was found that there were no significant dif- 
ferences in Lewis or Wistar rats with regard to distribu- 
tion of t61Tb-DTPA-octreotide (not shown). 161Tb- 
DTPA-octreotide is cleared even faster from the blood 
than UlIn-DTPA-octreotide: 20h after injection only 
0.0004% 1D was found in the blood (P<0.001 vs ~ In -  
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Effects of DTPA-octreotide (@) and of 159Tb-DTPA-octreotide 
(O) on secretion of rGH by cultured rat pituitary cells 
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Table 1. Radioactivity, expressed as % dose, in perfusion medi- 
um, bile and liver after 60 rain of perfusion with lIlIn-DTPA-oc- 
treotide (In-oc) or 16Wb-DTPA-octreotide (Tb-oc) 
Medium Bile Liver 
In-oc 95.9+-0.9 2.3_+0.2 1.7+0.2 
Tb-oc 99.6-+ 1.2* <0.1 * 1.4+0. l 
• P<0.001 versus 1HIn-DTPA-octreotide 
Table 2. Distribution of 0.2 MBq (0.5 btg) 11 lin_DTPA_octreotide 
and t6Wb-DTPA-octreotide n several organs of control rats, ex- 
pressed as % ID/g tissue, 20 h after administration 
Organ 11 lln-DTPA-octreotide 161Tb-DTPA-octreotide 
(% ID/g) (% ID/g) 
Blood 0.002_+0.0003 0.0004-+0.0001" 
Kidneys 1.52_+0.15 1.51 _+0.11 
Liver 0.061_+0.012 0.13+0.01" 
Pancreas 0.52_+0.12 0.23-+0.03* 
Spleen 0.03_+0.005 0.02-+0.001" 
Adrenals 0.76+0.10 0.184_+0.02" 
* P<O.001 versus 111 ln-DTPA-octreotide 
DTPA-octreotide). Kidney uptake of 161Tb-DTPA-oc- 
treotide and lllln-DTPA-octreotide was similarly high 
(1.5% ID). Liver uptake of 161Tb-DTPA-octreotide was 
higher than that of 111In-DTPA-octreotide (P<0.001), 
whereas the reverse was true for spleen, pancreas, and 
adrenals (P<0.001), the latter two organs possessing oc- 
treotide receptors. Table 3 shows that uptake of 16Wb- 
DTPA-octreotide and 11~in_DTPA_octreotide n pancreas 
and adrenals represents mostly specific binding to the 
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Table 3. Effect of pretreatment (40 min) with 0.5 lng unlabelled 
octreotide on the distribution of 16Wb-DTPA-octreotide and l llIn- 
DTPA-octreotide in the pancreas and adrenals (organs containing 
somatostatin receptors) of normal rats, expressed as % of control 
(=same tracer without pretreatment wi h unlabelled octreotide) 
Organ 11 lIn_DTPA_octreotide 161Tb_DTPA_octreotide 
(% control) (% control) 
Pancreas 1.92+0.20%* 4,34__0.18%* 
Adrenals 1.63-+0.22%* 4,52_+0.84%* 
* P<0.001 versus control 
octreotide receptors, as uptake in these organs was de- 
creased almost completely (P<0.001) by pretreatment of
the rats with 0.5 mg unlabelled octreotide. 
In Fig. 2 organ distribution of 16Wb-DTPA-octreo- 
tide, with or without pretreatment with unlabelled oc- 
treotide, is depicted in tumour-bearing rats 20 h after ad- 
ministration of 161Tb-DTPA-octreotide. The distribution 
in the tumour-bearing rats is the same as that seen in 
normal rats (Table 2). Uptake in colon, adrenals, pancre- 
as, pituitary and tumours appeared to represent mostly 
specific binding to octreotide receptors, as a major de- 
crease was observed after pretreatment with unlabelled 
octreotide (P<0.001). 
Influence of renal re-uptake blockers 
In Fig. 3 organ distribution of 161Tb-DTPA-octreotide, 
20 h after administration, is shown in the presence or ab- 
sence of lysine (400 mg/kg) or sodium maleate (400 
mg/kg), both potent blockers of the renal reabsorption 
process of lllIn-DTPA-octreotide in the proximal tubuli 
0.003[ 
0.0025I musc le  
control octreotide 
~ adr@nRJ~ 
control octrsotide 
controt octreotide control octreotide control octreotide control octreottde 
Fig. 2. Organ distribution of radioac- 
tivity [with (octreotide) orwithout 
(control) 40 min pretreatment wi h 
0.5 mg unlabelled octreotide] intu- 
mour-bearing rats, 20 h after adminis- 
tration of 161Tb-DTPA-octreotide 
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Fig. 3. Influence of sodium maleate (400 mg/kg) or lysine (lys; 400 mg/kg) on organ distribution ofradioactivity incontrol rats, 20 h after 
administration f 161Tb-DTPA-octreotide. * P<0.001 versus control 
[6]. Also for 161Tb-DTPA-octreotide, kidney uptake is 
inhibited significantly by both lysine and sodium male- 
ate, the latter being about twice as potent as the former, 
showing that also 161Tb-DTPA-octreotide is reabsorbed 
into the proximal tubular cells of the kidney after glom- 
erular filtration. After administration of lysine, uptake of 
label in all other organs is not different from the control 
situation, whereas after sodium maleate administration 
uptake of 161Tb-DTPA-octreotide is significanty in- 
creased compared to control (P<0.001). 
In Fig. 4, the influence of urinary flow on tubular e- 
absorption of i61Tb-DTPA-octreotide is depicted. It is 
shown that rats that eat dry rat chow (points on the left in 
the figure) produce less urine (range 5.1-7.5 ml/20h) 
than rats that eat food suspended in water (points on the 
right in the figure; range 12.8-23.1 ml/20 h). However, 
this increase in urine production on the day of the experi- 
ment did not influence the amount of radioactivity in the 
kidneys. This was also true when the increase in urine 
production was induced by change in diet 48 h before the 
administration of 161Tb-DTPA-octreotide (not shown). 
Influence of labelling efficiency on organ distribution 
161 of Tb-DTPA-octreotide 
In Fig. 5 it is shown that a maximal abelling efficiency 
is very important in achieving an optimal organ distribu- 
% ID/g kidney 2! 
I. • , '1 ,  • • • mnn • 
0.5 
0 
4 8 12 16 20 24 
ml urine/20 h 
Fig. 4. Influence of urinary flow during the experiment on kidney 
uptake of radioactivity in control rats, 20 h after administration f 
16]Tb_DTPA_octreotide 
tion of 161Tb-DTPA-octreotide. A labelling efficiency of 
100% means that all radioactivity administered to the 
rats was in the form of 161Tb-DTPA-octreotide, whereas 
0% means that it consisted of 16]TBC13, in the absence of 
DTPA-octreotide. For organs not possessing octreotide 
receptors, such as liver, spleen, femur and muscle, the 
uptake increased significantly with decreasing labelling 
efficiency (P<0.001 vs 100% labelling). In the kidneys, 
uptake is about the same for all situations, showing that 
the terbium not bound to octreotide is taken up with 
about the same efficiency as ~61Tb-DTPA-octreotide. 
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However, for octreotide receptor-possessing or ans, such 
as pancreas, adrenals and pituitary, it holds that a de- 
crease in labelling efficiency resulted in a significant de- 
crease in uptake of 16tTb-DTPA-octreotide in these or- 
gans. 
Influence of body mass on organ distribution 
of 161Tb-DTPA-octreotide 
In Fig. 6 the influence of body mass on the organ distri- 
bution of 161Tb-DTPA-octreotide is shown, 20 h after ad- 
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ministration. Three groups of rats with a body mass of 
360, 200 and 120 g were tested. It is shown that no sig- 
nificant differences were found in the uptake of 16Wb- 
DTPA-octreotide, expressed as % ID/g tissue, between 
the three groups with regard to liver, kidneys and spleen, 
organs that do not possess octreotide receptors. However, 
in pancreas and adrenals a significantly lower uptake 
was found in the 360-g group compared to the control 
(200-g) group. 
Discussion 
The results of the binding studies demonstrate hat 161Tb- 
DTPA-octreotide is a high-affinity radioligand for so- 
matostatin receptors, with an affinity comparable to that 
of 111In- DTPA-octreotide [4]. This was also demonstrat- 
ed in the in vivo experiments in control and tumour-bear- 
ing rats after the injection of 161Tb- DTPA-octreotide, in 
which uptake and specific binding in somatostatin recep- 
tor-positive tissues and tumour were found. Somatostatin 
receptors are structurally related integral membrane gly- 
coproteins. Recently, five different somatostatin receptor 
types have been cloned. All subtypes bind native somato- 
statin-14 (SS14) and SS2s (pro-somatostatin with 28 ami- 
no acids) with high affinity, while their affinity for nu- 
merous somatostatin analogues varies considerably 
[11-14]. Octreotide binds with high affinity to the 
SSTR2 (somatostatin receptor type 2) subtype, while this 
analogue has a relatively low affinity tbr SSTR3 and 
SSTR5 and shows no binding to SSTR subtypes 1 and 4 
[11-14]. Octreotide scintigraphy is therefore based on the 
visualization of octreotide-binding somatostatin receptors 
(octreotide r ceptors), most probably the SSTR2. 
Rat growth hormone secretion inhibition experiments 
showed that 161Tb- DTPA-octreotide has a similar poten- 
cy to 11Iin_ DTPA-octreotide [4]. 
The perfused rat liver is very suitable for the investi- 
gation of several parameters of liver uptake and excre- 
tion kinetics, such as the disappearance from the perfu- 
sion medium, appearance of degradation products and 
biliary excretion. 16Wb- DTPA-octreotide was taken up 
less by the isolated perfused rat liver than was mIn- 
DTPA-octreotide, as almost no tracer disappeared from 
the perfusion medium. Furthermore, hardly any radioac- 
tivity was found in the liver, and excretion into the bile 
was negligible. In order to find a tumour by intraopera- 
tive scanning in vivo, the specific activity expressed in 
counts per unit of area must exceed the local background 
radiation. As 161Tb- DTPA-octreotide is not cleared via 
the liver and thus causes no accumulation of radioactivi- 
ty in biliary and digestive tract, this radiopharmaceutical 
would be suitable for scanning Of tumour eceptor accu- 
mulation in the upper abdominal region, where many of 
the small endocrine gastro-entero-pancreatic target tu- 
mours are located. 
However, the in vivo liver uptake is not in agreement 
with the liver perfusion studies; in vivo we find a higher 
liver uptake of 161Tb- DTPA-octreotide than of Hqn- 
DTPA-octreotide, 20 h after administration. At present, 
the reason for this discrepancy between in vivo and in 
vitro findings is not clear and is currently being investi- 
gated. It could be explained by less stable intact 161Tb- 
DTPA-octreotide after in vivo administration than ~j ~In- 
DTPA-octreotide, so degradation products of ~61Tb- 
DTPA-octreotide could cause the higher liver uptake 
found in vivo. However, the product is stable in serum 
for 24 h as measured with Sephadex PD-10 chromatog- 
raphy (not shown), so this explanation is not likely. 
Our findings in Table 2 show that for octreotide re- 
ceptor-positive organs, such as pancreas and adrenals, 
uptake of i6~Tb- DTPA-octreotide is lower than that of 
rain- DTPA-octreotide. However, as the clearance from 
the blood of the former compound is faster than that of 
the latter, the tissue/blood ratio is higher with 16Wb- 
DTPA-octreotide than with 1HIn- DTPA-octreotide. In 
the case of tumours this is a favourable situation for in- 
traoperative scanning. 
As for the high uptake in the kidneys: small peptides 
in the blood plasma are filtered through the glomerular 
capillaries in the kidneys and subsequently reabsorbed 
almost completely (_>90%) by the proximal tubular cells 
via carrier-mediated ndocytosis. This is also the case 
for the radiolabelled octapeptides l llIn- DTPA-octreo- 
tide and 161Tb- DTPA-octreotide. After the subsequent 
degradation process that takes place in the lysosomes of 
the tubular cells, their labelled degradation products are 
"trapped" in the lysosomes [15], causing a high dose of 
radioactivity in the kidneys. This study in vivo in rats 
demonstrates that the uptake of 161Tb- DTPA-octreotide 
by the renal tubular cells after glomerular filtration can 
be reduced by administration of lysine or sodium male- 
ate. As for lysine, the membranes of renal tubular cells 
contain negatively charged sites, to which positively 
charged residues of peptides or proteins are thought o 
bind [16]. An inhibition of this binding process may ex- 
plain the effects of administration of the positively 
charged amino acid lysine on nlIn- DTPA-octreotide re- 
uptake [6, 17, 18]. The most pronounced effect on tubu- 
lar re-uptake of 161Tb- DTPA-octreotide in this study 
was exerted by sodium maleate (Fig. 3). Sodium maleate 
has been used to create and study renal tubular dysfunc- 
tion comparable to the human Fanconi's syndrome [19, 
20], resulting in aminoaciduria nd proteinuria. This 
compound forms maleyl-CoA by reacting with succinyl- 
CoA, thereby reducing the cellular CoA supply and in- 
hibiting the citirc acid cycle in tubular cells [21]. The re- 
sulting reduced ATP supply or the reaction of the male- 
yl-CoA with membrane proteins may inhibit a variety of 
renal transport systems, including peptide re-absorption 
[21]. The inhibitory effect of sodium maleate, as found 
in this study, thus indicates that the re-absorption pro- 
cess of 16Wb- DTPA-octreotide into the renal tubular 
cells is energy dependent. The increase in the uptake of 
i61Tb- DTPA-octreotide in all organs by sodium maleate 
(except for the kidneys), as shown in Fig. 3, may be ex- 
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plained by the inhibitory effect of this compound on the 
renal glomerular filtration rate [22]. 
Increase in urine production before and during the ex- 
periment had no effect on the kidney uptake of 161Tb- 
DTPA-octreotide (Fig. 4). The increase in urine produc- 
tion was induced by feeding the rats with chow suspend- 
ed in water. However, re-uptake of peptides in the renal 
tubules is not influenced by an increased urinary flow 
through the kidneys. The results found here for 161Tb- 
DTPA-octreotide are in agreement with those for 111In- 
DTPA-octreotide [6]. 
Figure 5 shows that a maximal abelling efficiency of 
161Tb-DTPA-octreotide is essential, as with decreasing 
efficiency the uptake in the octreotide receptor-positive 
organs decreases, whereas non-specific uptake in the 
other organs is increased. Even when labelling efficiency 
was 93%, the effects on organ distribution were signifi- 
cantly different (P<0.001) compared with 100% label- 
ling efficiency. This decreased specific binding in com- 
bination with increased non-specific binding is, or 
course, very unfavourable for both intraoperative scan- 
ning and radiotherapy. 
The effect of rat body mass on 161Tb- DTPA-octreo- 
tide organ distribution is shown in Fig. 6. As rats gain 
weight during their whole life, increase in body mass is 
paralleled by an increase in age and development. Since 
the same dose of 161Tb- DTPA-octreotide was adminis- 
tered to the different groups (with widely different distri- 
bution volumes), it is not surprising that uptake in all or- 
gans studied is highest in the low-body-mass rats, while 
uptake is lowest is the high-body-mass animals. Howev- 
er, for adrenals and pancreas, both octreotide receptor- 
positive organs, the decrease in uptake in the 360-g 
group was much more pronounced than in the octreotide 
receptor-negative organs. This finding may point to de- 
velopmental changes in expression of the octreotide re- 
ceptor in these organs, as has been found for other so- 
matostatin receptor-positive organs, such as the rat brain 
and the rat visual system [23, 24]. 
In conclusion: Based on the characteristics of ~61Tb 
(low-energy gamma rays, hard beta rays, and a half-life 
of nearly 7 days) combined with the in vitro binding 
studies, biological acticity, and in vivo organ distribution 
of 161Tb- DTPA-octreotide, the latter may be considered 
a promising radiopharmaceutical for both intraoperative 
scanning and radiotherapy. Further studies in patients 
need to be performed now to see whether 161Tb- DTPA- 
octreotide can indeed open new therapeutic applications 
for patients bearing octreotide receptor-positive tu- 
mours. 
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